10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2017 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Sales | $ 40,122 | 39,807 | 39,498 |
| Costs, Expenses and Other | |||
| Materials and production | 12,775 | 13,891 | 14,934 |
| Marketing and administrative | 9,830 | 9,762 | 10,313 |
| Research and development | 10,208 | 10,124 | 6,704 |
| Restructuring costs | 776 | 651 | 619 |
| Other (income) expense, net | 12 | 720 | 1,527 |
| Total Costs, Expenses and Other | 33,601 | 35,148 | 34,097 |
| Income Before Taxes | 6,521 | 4,659 | 5,401 |
| Taxes on Income | 4,103 | 718 | 942 |
| Net Income | 2,418 | 3,941 | 4,459 |
| Less: Net Income Attributable to Noncontrolling Interests | 24 | 21 | 17 |
| Net Income Attributable to Merck & Co., Inc. | 2,394 | 3,920 | 4,442 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 0.88 | 1.42 | 1.58 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 0.87 | 1.41 | 1.56 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2017 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Net Income Attributable to Merck & Co., Inc. | $ 2,394 | 3,920 | 4,442 |
| Other Comprehensive Income (Loss) Net of Taxes: | |||
| Net unrealized loss on derivatives, net of reclassifications | (446) | (66) | (126) |
| Net unrealized loss on investments, net of reclassifications | (58) | (44) | (70) |
| Benefit plan net gain (loss) and prior service credit (cost), net of amortization | 419 | (799) | 579 |
| Cumulative translation adjustment | 401 | (169) | (208) |
| Other comprehensive income (loss), net of taxes | 316 | (1,078) | 175 |
| Comprehensive Income Attributable to Merck & Co., Inc. | 2,710 | 2,842 | 4,617 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2017 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 2,418 | 3,941 | 4,459 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 4,637 | 5,441 | 6,375 |
| Intangible asset impairment charges | 646 | 3,948 | 162 |
| Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation | 5,347 | 0 | 0 |
| Charge for future payments related to AstraZeneca collaboration license options | 500 | 0 | 0 |
| Charge related to the settlement of worldwide Keytruda patent litigation | 0 | 625 | 0 |
| Foreign currency devaluation related to Venezuela | 0 | 0 | 876 |
| Net charge related to the settlement of Vioxx shareholder class action litigation | 0 | 0 | 680 |
| Equity income from affiliates | (42) | (86) | (205) |
| Dividends and distributions from equity method affiliates | 2 | 16 | 50 |
| Deferred income taxes | (2,621) | (1,521) | (764) |
| Share-based compensation | 312 | 300 | 299 |
| Other | 269 | 313 | 874 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 297 | (619) | (480) |
| Inventories | (145) | 206 | 805 |
| Trade accounts payable | 254 | 278 | (37) |
| Accrued and other current liabilities | (922) | (2,018) | (8) |
| Income taxes payable | (3,291) | 124 | (266) |
| Noncurrent liabilities | (123) | (809) | (277) |
| Other | (1,091) | 237 | (5) |
| Net Cash Provided by Operating Activities | 6,447 | 10,376 | 12,538 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,888) | (1,614) | (1,283) |
| Purchases of securities and other investments | (10,739) | (15,651) | (16,681) |
| Proceeds from sales of securities and other investments | 15,664 | 14,353 | 20,413 |
| Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired | 0 | 0 | (7,598) |
| Acquisitions of other businesses, net of cash acquired | (396) | (780) | (146) |
| Dispositions of businesses, net of cash divested | 0 | 0 | 316 |
| Other | 38 | 482 | 221 |
| Net Cash Provided by (Used in) Investing Activities | 2,679 | (3,210) | (4,758) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (26) | 0 | (1,540) |
| Payments on debt | (1,103) | (2,386) | (2,906) |
| Proceeds from issuance of debt | 0 | 1,079 | 7,938 |
| Purchases of treasury stock | (4,014) | (3,434) | (4,186) |
| Dividends paid to stockholders | (5,167) | (5,124) | (5,117) |
| Proceeds from exercise of stock options | 499 | 939 | 485 |
| Other | (195) | (118) | (61) |
| Net Cash Used in Financing Activities | (10,006) | (9,044) | (5,387) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 457 | (131) | (1,310) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (423) | (2,009) | 1,083 |
| Cash and Cash Equivalents at Beginning of Year | 6,515 | 8,524 | |
| Cash and Cash Equivalents at End of Year | 6,092 | 6,515 | 8,524 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2017 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2017 | Dec 31, 2016 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 6,092 | 6,515 |
| Short-term investments | 2,406 | 7,826 |
| Accounts receivable (net of allowance for doubtful accounts of $210 in 2017 and $195 in 2016) | 6,873 | 7,018 |
| Inventories (excludes inventories of $1,187 in 2017 and $1,117 in 2016 classified in Other assets - see Note 7) | 5,096 | 4,866 |
| Other current assets | 4,299 | 4,389 |
| Total current assets | 24,766 | 30,614 |
| Investments | 12,125 | 11,416 |
| Property, Plant and Equipment (at cost) | ||
| Land | 365 | 412 |
| Buildings | 11,726 | 11,439 |
| Machinery, equipment and office furnishings | 14,649 | 14,053 |
| Construction in progress | 2,301 | 1,871 |
| Property, plant and equipment (at cost) | 29,041 | 27,775 |
| Less: accumulated depreciation | 16,602 | 15,749 |
| Property, plant and equipment, net | 12,439 | 12,026 |
| Goodwill | 18,284 | 18,162 |
| Other Intangibles, Net | 14,183 | 17,305 |
| Other Assets | 6,075 | 5,854 |
| Total Assets | 87,872 | 95,377 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 3,057 | 568 |
| Trade accounts payable | 3,102 | 2,807 |
| Accrued and other current liabilities | 10,427 | 10,274 |
| Income taxes payable | 708 | 2,239 |
| Dividends payable | 1,320 | 1,316 |
| Total current liabilities | 18,614 | 17,204 |
| Long-Term Debt | 21,353 | 24,274 |
| Deferred Income Taxes | 2,219 | 5,077 |
| Other Noncurrent Liabilities | 11,117 | 8,514 |
| Merck & Co., Inc. Stockholders Equity | ||
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2017 and 2016 | 1,788 | 1,788 |
| Other paid-in capital | 39,902 | 39,939 |
| Retained earnings | 41,350 | 44,133 |
| Accumulated other comprehensive loss | (4,910) | (5,226) |
| Stockholders' equity before deduction for treasury stock | 78,130 | 80,634 |
| Less treasury stock, at cost: 880,491,914 shares in 2017 and 828,372,200 shares in 2016 | 43,794 | 40,546 |
| Total Merck & Co., Inc. stockholders equity | 34,336 | 40,088 |
| Noncontrolling Interests | 233 | 220 |
| Total equity | 34,569 | 40,308 |
| Total Liabilities and Equity | 87,872 | 95,377 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |